The term “reversal” in the context of Multiple Sclerosis (MS) often sparks hope, conjuring images of significant symptomatic improvement. While clinically this refers to a reduction in or disappearance of symptoms, a deeper, evidence-based understanding reveals a more intricate reality. Similar to the elusive concept of a “cure” in MS – which can range from halting new symptoms to stabilizing lesion changes or lessening existing ones – reversal is multifaceted. The trajectory of an individual’s MS journey is profoundly influenced by a unique interplay of factors, including age, current disability, genetic predispositions, immune and neuroendocrine health, nutritional status, secondary biomechanical issues, and the burden of drug side effects.
Even when a therapeutic strategy thoughtfully addresses many crucial aspects of MS, individual outcomes can vary considerably due to these pre-existing factors. Therefore, the mechanisms underlying reversal are not solely dependent on the chosen therapy but also on the individual’s inherent capacity to overcome the underlying disease pathology. A fascinating example of this is seen in relapsing-remitting MS, where individuals at earlier stages can often demonstrate a degree of self-repair through neuroplasticity, mitigating neurodegeneration and demyelination before irreversible fibrotic changes take hold – that is, until the next episode of immune-mediated, ischemic, or cytotoxic damage occurs. This highlights the remarkable ability of some individuals with MS to counteract ongoing degenerative processes, a capacity significantly shaped by lifestyle and environmental influences. Furthermore, a notable number of individuals with chronic MS experience periods of stability without the need for disease-modifying therapies (DMTs) or immunosuppressants. Often, those in this stable category who do opt for conventional treatments may attribute their stabilization to these medications, a perception sometimes reinforced by well-meaning but potentially incomplete communication from neurologists. In reality, improvements might be significantly driven by positive changes in their lifestyle and environment.
However, the role of conventional medicine in definitively halting MS progression remains a complex and debated issue, particularly given that a significant portion of MS cases show no active autoimmune behavior as indicated by standard autoantibody tests. Conversely, there’s a growing recognition that certain interventions – paradoxically often attributed to MS management – can inadvertently hinder meaningful healing in individuals who might otherwise manage their condition effectively through other means. The chronic immunodeficiency resulting from long-term immunosuppressant use, the potential for excessive hematopoietic fibrosis from autologous hematopoietic transplants (originally developed for cancer treatment), the suppression of neuroplasticity through muscle relaxants, and the detrimental effects on the central nervous system from medications like anticonvulsants, benzodiazepines, and selective serotonin reuptake inhibitors are all contemporary examples of how MS symptoms might be inadvertently exacerbated while these side effects are often minimized in discussions.
The serious immune-related adverse events, the risk of irreversible hematopoietic fibrosis, the natural process of aging compounded by treatment burdens, the challenging drug withdrawal symptoms, and the potential for dependency associated with conventional MS therapies suggest a need to move beyond simply managing the disorder. For individuals with MS who demonstrate an ability to control their condition without exacerbating it through aggressive interventions, non-conventional methods that extend beyond standard clinical practices may hold promise.
Adopting a perspective focused on meaningful recovery necessitates a deep understanding of each individual’s unique MS presentation, which often involves a distinct constellation of contributing factors. One of the significant limitations of conventional MS management lies in its often standardized approach, failing to fully account for this heterogeneity. While the halting of disease progression is indeed observed in MS, the necessity for repeat treatments is an economic reality within the healthcare system. Consequently, we may be introducing substances into our bodies that offer temporary symptomatic relief but potentially contribute to long-term symptoms that can mimic or worsen the underlying MS. With such complex interferences in the body’s natural dynamics, achieving sustainable and truly curative approaches is likely to yield varied results. Alongside a more nuanced clinical understanding of MS, rigorous research aimed at identifying specific markers that reflect the true impact of conventional treatments is crucial in determining how an unconventional treatment – such as regenerative therapy – might affect an MS patient whose current symptoms may, in part, be a consequence of prior treatments.
It is vital to acknowledge that the limitations of current conventional MS management do not automatically equate to the superiority of all unconventional approaches. In fact, therapies administered in unregulated environments often carry a heightened risk of failure due to the absence of established clinical ethics and accountability. Therefore, such options must be approached with considerable caution and critical evaluation. Ultimately, moving towards a more effective future for MS management requires a proactive re-education about your individual MS experience to empower informed choices before critical junctures are reached. Seek comprehensive information, understand the common threads that connect your experience with others living with MS, and, most importantly, identify the unique aspects that define your specific symptom profile. This personalized understanding is the crucial first step towards navigating the complex landscape of MS and pursuing the most appropriate path forward.
—– AUTHOR STATEMENT —-
This article discusses the subjectivity of the terms ‘reversal’ and ‘cure’ in relation to the multifaceted phases of Multiple Sclerosis (MS). I am a neurobiologist with 20 years of experience working with MS patients. This article references both widely known facts highlighted in various studies and lesser-known information, such as the lack of testing for autoantibodies before prescribing immunosuppressants to patients diagnosed with autoimmune symptoms.
It is a well-established fact within the MS community that individuals with Relapsing-Remitting MS (RRMS) can sometimes overcome lesion load, which slows the progression of the disease. Conversely, progressive forms of MS tend to be more severe.
Many MS patients have been able to maintain their condition without progression for extended periods without the need for Disease-Modifying Therapies (DMTs). Additionally, it is also well-documented that some patients on DMTs continue to experience progression.
Immunosuppressants are known to cause immunodeficiency, which is a common understanding in the medical community, requiring no additional sources to support this claim.
A lesser-known risk associated with Hematopoietic Stem Cell Transplantation (HSCT) is hematopoietic fibrosis, which can lead to myelofibrosis. I will provide a reference for this: “Graft-versus-host disease and its impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation” [https://doi.org/10.1038/s41409-024-02220-7].
Muscle relaxants such as baclofen have a neurosuppressive effect. While they temporarily alleviate muscle spasticity by reducing motor nerve conduction, their neurosuppressive nature, along with their toxicity and withdrawal effects, can hinder brain electrochemistry and neuroplasticity—the mechanism through which the adult brain responds to neurodegeneration. Here’s a reference regarding baclofen’s lesser-known effects on an MS-affected brain striving to recover: “Baclofen therapeutics, toxicity, and withdrawal: A narrative review” [https://doi.org/10.1177/20503121211022197].
Additionally, there are distinct effects of benzodiazepines (about which I have written another article), anticonvulsants like Gabapentin, and SSRIs. I plan to address these medications individually in my upcoming articles. Numerous studies exist regarding the effects of each.
The article further emphasizes the need for research focused on overcoming challenges rather than simply managing symptoms or suppressing autoimmunity, which may not always be present. It highlights how blind treatments can exacerbate existing issues.
In conclusion, the article calls for personalized diagnosis and targeted therapeutics in MS. This is an area in which I have extensively worked, and many in this group can attest to my efforts. I acknowledge that my attempts to raise MS awareness have been modest, as I have not been very active on social media. However, I wish to improve my efforts in educating individuals affected by this condition.